Rockwell Medical (RMTI) Gains from Investment Securities (2017 - 2020)
Rockwell Medical (RMTI) posted Gains from Investment Securities of $837000.0 for Q2 2020, up 76.63% on a QoQ basis from $473871.0 in Q2 2017.
Rockwell Medical (RMTI) Gains from Investment Securities (2017 - 2020) Analysis & Trends
Rockwell Medical's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $837000.0 for Q2 2020.
- Quarterly Gains from Investment Securities changed N/A year-over-year to $837000.0 in Q2 2020, while the trailing twelve-month figure through Jun 2021 was $837000.0 (changed 0.0% YoY) and the FY2025 annual result came in at $77000.0, up 28.33% from the prior year.
- Gains from Investment Securities was $837000.0 for Q2 2020 at Rockwell Medical, up from $473871.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $837000.0 in Q2 2020 and bottomed at $473871.0 in Q2 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Rockwell Medical | 27.99 Mn | 4.10 Mn | 2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 837,000.00 |
| Jun 30, 2020 | 837,000.00 |
| Jun 30, 2017 | 473,871.00 |
| Jun 30, 2017 | 473,871.00 |